Shennon Biotechnologies
Private Company
Funding information not available
Overview
Shennon Biotechnologies is a private, preclinical-stage biotech founded in 2018 and headquartered in San Francisco, CA. The company has developed the TCELERATOR™ platform, which combines ultrafast functional screening of single-cell interactions with proprietary AI models to identify novel therapeutic targets and agents, primarily in immuno-oncology and autoimmunity. Backed by a $13M seed round and a team with deep expertise in immunology, single-cell analysis, and drug development, Shennon aims to de-risk and accelerate early-stage drug discovery by moving from phenotypic screening directly to target identification and candidate building.
Technology Platform
TCELERATOR™ platform combining ultrafast, high-throughput functional screening of millions of single cell-cell interactions with proprietary AI models to identify novel therapeutic targets and drug candidates.
Opportunities
Risk Factors
Competitive Landscape
Shennon competes in the crowded field of AI/ML for drug discovery (e.g., Recursion, Exscientia) and high-throughput single-cell screening platforms. Its differentiation lies in the direct integration of ultrafast *functional* interaction mapping with AI for target deconvolution, a focus on cell-cell interactions, and a specialized team in immunology and single-cell physics.